期刊文献+

注射用重组人组织型纤溶酶原激酶衍生物不同给药方式治疗急性肺栓塞的效果及安全性研究 被引量:11

Retrospective Analysis of Efficacy and Safety between Different Administrations of Reteplase Via Venous Pump in Treatment of Acute Pulmonary Embolism
下载PDF
导出
摘要 目的研究注射用重组人组织型纤溶酶原激酶衍生物(reteplase,r-PA)静脉泵注对急性肺栓塞(pulmonary embolus,PE)溶栓治疗的临床效果及安全性。方法选取我院2012年1月—2014年4月符合溶栓指征的急性PE患者76例,根据溶栓用药种类和给药方法的不同分为r-PA静脉泵注组17例、r-PA静脉推注组32例和尿激酶组27例。r-PA静脉泵注组应用注射用r-PA 18 mg加0.9%氯化钠注射液50 ml 2 h内缓慢静脉泵入;r-PA静脉推注组应用注射用r-PA两次缓慢静脉推注,每次18 mg,推注间隔30 min,每次推注时间≥2 min;尿激酶组予尿激酶20 000 U/kg加0.9%氯化钠注射液100 ml 2 h内静脉滴注。溶栓治疗后常规予华法林及低分子肝素抗凝。观察比较溶栓治疗前及治疗后7 d肺动脉再通率、动脉血氧分压(Pa O2)及肺动脉平均压的变化以评价溶栓治疗效果,并观察各组溶栓后并发症发生情况和30 d病死率。结果 3组治疗前后肺动脉再通率、Pa O2及肺动脉平均压比较差异均有统计学意义(P<0.01)。治疗后,r-PA静脉泵注组总有效率显著高于r-PA静脉推注组和尿激酶组(P<0.05);r-PA静脉泵注组30 d病死率为0,低于r-PA静脉推注组的25.00%和尿激酶组的22.22%(P<0.05)。3组溶栓后出血率差异无统计学意义(P>0.05)。结论静脉缓慢泵注r-PA治疗急性PE的成功率不低于《肺血栓栓塞症的诊断与治疗指南》规定的传统溶栓治疗方法,且治疗后出血发生率及病死率下降,可能是一种更安全、有效的PE溶栓治疗方法。 Objective To compare the clinical efficacy and safety between different administrations of domestic reteplase via venous pump in thrombolysis of acute pulmonary embolism. Methods 49 patients with acute pulmonary embolism hospitalized in our center during January 2012 and April 2014 were retrospective analyzed and treated with reteplase. Among them,17 patients received reteplase at a dose of 18 mg via venous pump in 2 hours; the other 32 patients were treated with reteplase according to the traditional instruction,namely double intravenous injection with an interval of 30 minutes; in addition,27 patients with acute pulmonary embolism were chosen as control group,who underwent urokinase thrombolysis according to guidelines,and then we observed the recanalization,hemorrhage reaction and 30-day mortality rate respectively. Results The recanalization rates,Pa O2 and the mean pulmonary artery pressure before and after treatment of the three groups showed significant differences( P〈0. 01). After treatment,thrombolysis efficient rate of group P was the highest and there was statistically significant difference compared with group T and control group. 30 d mortality rate of r-PA venous pump group was zero,lower than that of the other two groups( 25. 00% and 22. 22%,P〈0. 05) and there was no significant difference in the hemorrhage reaction rates between the three groups( P〉0. 05). Conclusion Patients with acute pulmonary embolism undergoing treatment with domestic reteplase by pumping r-PA slowly can achieve similar effect with the traditional thrombolytic method and the hemorrhage and mortality rates are significantly decreased. It is a more effective and safer method in treating PE.
出处 《临床误诊误治》 2015年第10期89-92,共4页 Clinical Misdiagnosis & Mistherapy
关键词 重组人组织型纤溶酶原激酶衍生物 肺栓塞 尿激酶型纤溶酶原激活物 输注泵 Reteplase Pulmonary embolism Urokinase-type plasminogen activator Infusion pump
  • 相关文献

参考文献17

二级参考文献45

  • 1胡大一.急性心肌梗塞链激酶静脉溶栓疗法的多中心试验[J].中华心血管病杂志,1994,22(6):403-405. 被引量:60
  • 2ResearchGroupofNationalProject85-915-02-01(Correspondence:FuWaiHospi-tal,CAMS&PUMC,Beijing100037).急性心肌梗塞尿激酶临床应用研究(1138例)[J].中华心血管病杂志,1996,24(3):169-173. 被引量:156
  • 3国家'十五'攻关'肺栓塞规范化诊治方法的研究'课题组,吴雅峰,王辰,张栋,杨媛华.超声心动图检测右心功能指标对急性肺栓塞不同治疗方法的评价[J].中国循环杂志,2007,22(1):41-44. 被引量:13
  • 4蔡柏蔷,李龙芸.协和呼吸病学[M].2版.北京:中国协和医科大学出版社,2006:805. 被引量:4
  • 5The collaborative study group for national multicenter clinical trial of urokinase thrombolytic therapy (Correspondence: Hu Dayi, Xu Zhimin. Beijing Red Cross Chao Yao Hospital, Beijing 100020).尿激酶治疗急性心肌梗塞多中心临床试验1406例总结[J].中华心血管病杂志,1997,25(3):176-179. 被引量:138
  • 6中华医学会呼吸病学分会.肺血栓栓塞症的诊断与治疗指南[J]中华结核和呼吸杂志,2001(05). 被引量:3
  • 7Apfaltrer P,Henzler T,Meyer M,et al.Correlation of CT angiographic pulmonary artery obstruction scores with right ventricular dysfunction and clinical outcome in patients with acute pulmonary embolism[J].European Journal of Radiology,2012,81(10):2867-2871. 被引量:1
  • 8Golpe R,De Llano LAP,Castro-Aón O,et al.Long-term outcome of patients with persistent vascular obstruction on computed tomography pulmonary angiography 6 months after acute pulmonary embolism[J].Acta Radiologica,2012,53(7):728-731. 被引量:1
  • 9Torbieki A, Perrier A, Konstantinides S, et al. Guidelines on the di- agnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embol- ism of the European Society of Cardiology (ESC) [J]. Eur Heart J, 2008, 29(18) :2276 -2315. 被引量:1
  • 10Tapson VF. Acute pulmonary embolism [ J ]. N Engl J Med, 2008, 358 (10) : 1037 - 1052. 被引量:1

共引文献2100

同被引文献169

  • 1周晓辉,贺春钰.缺血性脑血管病与颈动脉粥样硬化及其危险因素的关系[J].临床神经病学杂志,2005,18(5):370-372. 被引量:47
  • 2胡大一,张鹤萍,孙艺红,姜立清.华法林与阿司匹林预防非瓣膜性心房颤动患者血栓栓塞的随机对照研究[J].中华心血管病杂志,2006,34(4):295-298. 被引量:162
  • 3邹治鹏,何建国,程显声,赵彦芬,陈白屏,高莹,熊长明,倪新海,荆志诚.230例急性肺动脉血栓栓塞症患者对症治疗、抗凝治疗和溶栓治疗的住院转归[J].中国循环杂志,2006,21(3):219-221. 被引量:27
  • 4WolfeTR, AllenTL. Syncope as an emergency department presentation of pulmonary embolism[J]. J Emerg Med, 16(1):27–31. 被引量:1
  • 5KonstantinidesSV. 2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism[J]. Eur Heart J, 2014, 35(45): 3145–3146. DOI:10.1093/eurheartj/ehu393. 被引量:1
  • 6HeitJA. The epidemiology of venous thromboembolism in the community[J]. Arterioscler Thromb Vasc Biol, 2008,28(3):370–372.DOI: 10.1161/ATVBAHA.108.162545. 被引量:1
  • 7CohenAT, AgnelliG, AndersonFA, et al. Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality[J]. Thromb Haemost, 2007,98(4):756–764. 被引量:1
  • 8YangY, LiangL, ZhaiZ, et al. Pulmonary embolism incidence and fatality trends in chinese hospitals from 1997 to 2008: a multicenter registration study[J]. PLoS One, 2011,6(11):e26861.DOI: 10.1371/journal.pone.0026861. 被引量:1
  • 9LaporteS, MismettiP, DécoususH, et al. Clinical predictors for fatal pulmonary embolism in 15,520 patients with venous thromboembolism: findings from the Registro Informatizado de la Enfermedad TromboEmbolica venosa (RIETE) Registry[J]. Circulation, 2008,117(13):1711–1716.DOI: 10.1161/CIRCULATIONAHA.107.726232. 被引量:1
  • 10GoldhaberSZ, VisaniL, De RosaM. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER)[J]. Lancet, 1999,353(9162):1386–1389. 被引量:1

引证文献11

二级引证文献673

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部